Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Perspective: Biophysical regulation of cancerous and normal blood cell lineages in hematopoietic malignancies.

Wong SW, Lenzini S, Shin JW.

APL Bioeng. 2018 May 22;2(3):031802. doi: 10.1063/1.5025689. eCollection 2018 Sep.

2.

Improving hematopoietic recovery through modeling and modulation of the mesenchymal stromal cell secretome.

Liu FD, Tam K, Pishesha N, Poon Z, Van Vliet KJ.

Stem Cell Res Ther. 2018 Oct 24;9(1):268. doi: 10.1186/s13287-018-0982-2.

3.

To grab the stroma by the horns: from biology to cancer therapy with mesenchymal stem cells.

Droujinine IA, Eckert MA, Zhao W.

Oncotarget. 2013 May;4(5):651-64. Review.

4.

RNA-binding proteins in hematopoiesis and hematological malignancy.

Hodson DJ, Screen M, Turner M.

Blood. 2019 May 30;133(22):2365-2373. doi: 10.1182/blood-2018-10-839985. Epub 2019 Apr 9. Review.

PMID:
30967369
5.

Mechanobiology of mesenchymal stem cells: Perspective into mechanical induction of MSC fate.

Hao J, Zhang Y, Jing D, Shen Y, Tang G, Huang S, Zhao Z.

Acta Biomater. 2015 Jul;20:1-9. doi: 10.1016/j.actbio.2015.04.008. Epub 2015 Apr 11. Review.

PMID:
25871537
6.

Novel Immunotherapies for Hematological Malignancies.

Vasekar M, Rizvi S, Liu X, Vrana KE, Zheng H.

Curr Mol Pharmacol. 2016;9(3):264-271. Review.

PMID:
26177640
7.

Mesenchymal Stromal Cells in Hematopoietic Stem Cell Transplantation.

Bernardo ME, Locatelli F.

Methods Mol Biol. 2016;1416:3-20. doi: 10.1007/978-1-4939-3584-0_1.

PMID:
27236663
8.

Multiple Roles of Glycans in Hematological Malignancies.

Pang X, Li H, Guan F, Li X.

Front Oncol. 2018 Sep 6;8:364. doi: 10.3389/fonc.2018.00364. eCollection 2018. Review.

9.

Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).

Foffi G, Pastore A, Piazza F, Temussi PA.

Phys Biol. 2013 Aug;10(4):040301. Epub 2013 Aug 2.

PMID:
23912807
10.

Mesenchymal stem cell insights: prospects in hematological transplantation.

Chou SH, Lin SZ, Day CH, Kuo WW, Shen CY, Hsieh DJ, Lin JY, Tsai FJ, Tsai CH, Huang CY.

Cell Transplant. 2013;22(4):711-21. doi: 10.3727/096368912X655172. Epub 2012 Nov 27. Review.

PMID:
23190451
11.

Human-derived normal mesenchymal stem/stromal cells in anticancer therapies.

Zhang C, Yang SJ, Wen Q, Zhong JF, Chen XL, Stucky A, Press MF, Zhang X.

J Cancer. 2017 Jan 1;8(1):85-96. doi: 10.7150/jca.16792. eCollection 2017. Review.

12.

[The use of mesenchymal stromal cells in oncology and cell therapy].

Pommey S, Galipeau J.

Bull Cancer. 2006 Sep;93(9):901-7. Review. French.

13.

Mesenchymal stem cells in the colorectal tumor microenvironment: recent progress and implications.

Hogan NM, Dwyer RM, Joyce MR, Kerin MJ.

Int J Cancer. 2012 Jul 1;131(1):1-7. doi: 10.1002/ijc.27458. Epub 2012 Feb 28. Review.

14.

Are mesenchymal stromal cells immune cells?

Hoogduijn MJ.

Arthritis Res Ther. 2015 Mar 31;17:88. doi: 10.1186/s13075-015-0596-3. Review.

15.

Microarray Gene Expression Analysis to Evaluate Cell Type Specific Expression of Targets Relevant for Immunotherapy of Hematological Malignancies.

Pont MJ, Honders MW, Kremer AN, van Kooten C, Out C, Hiemstra PS, de Boer HC, Jager MJ, Schmelzer E, Vries RG, Al Hinai AS, Kroes WG, Monajemi R, Goeman JJ, Böhringer S, Marijt WA, Falkenburg JH, Griffioen M.

PLoS One. 2016 May 12;11(5):e0155165. doi: 10.1371/journal.pone.0155165. eCollection 2016.

16.

Novel aspects of parenchymal-mesenchymal interactions: from cell types to molecules and beyond.

Bluguermann C, Wu L, Petrigliano F, McAllister D, Miriuka S, Evseenko DA.

Cell Biochem Funct. 2013 Jun;31(4):271-80. doi: 10.1002/cbf.2950. Epub 2013 Jan 12. Review.

PMID:
23315627
17.

Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway.

Katanov C, Lerrer S, Liubomirski Y, Leider-Trejo L, Meshel T, Bar J, Feniger-Barish R, Kamer I, Soria-Artzi G, Kahani H, Banerjee D, Ben-Baruch A.

Stem Cell Res Ther. 2015 May 1;6:87. doi: 10.1186/s13287-015-0080-7.

18.

Allo-reactive T cells for the treatment of hematological malignancies.

Falkenburg JH, Jedema I.

Mol Oncol. 2015 Dec;9(10):1894-903. doi: 10.1016/j.molonc.2015.10.014. Epub 2015 Oct 24. Review.

19.

Involvement of mesenchymal stem cells in cancer progression and metastases.

Chang AI, Schwertschkow AH, Nolta JA, Wu J.

Curr Cancer Drug Targets. 2015;15(2):88-98. Review.

PMID:
25619387
20.

Extracellular Vesicles: A New Prospective in Crosstalk between Microenvironment and Stem Cells in Hematological Malignancies.

Laurenzana I, Lamorte D, Trino S, De Luca L, Ambrosino C, Zoppoli P, Ruggieri V, Del Vecchio L, Musto P, Caivano A, Falco G.

Stem Cells Int. 2018 May 27;2018:9863194. doi: 10.1155/2018/9863194. eCollection 2018. Review.

Supplemental Content

Support Center